Alabama bill targets andro, DHEA
This article was originally published in The Tan Sheet
Executive Summary
The sale of dietary supplements containing androstanedione, dehydroepiandrosterone or ephedrine alkaloids to consumers under 18 years of age would be prohibited under a bill recently introduced in the Alabama state legislature. The proposal requires that sellers obtain valid identification from purchasers, and makes violation of the law a Class A misdemeanor. HB 356, sponsored by Rep. Tommy Sherer (D) and House Majority leader Ken Guin (D), was referred to the Health Committee March 15. In other DHEA-related legislative activity, an Oregon state bill would bar school employees from endorsing use of performance-enhancing supplements by students, while a federal bill by Sen. Charles Grassley, R-Iowa, would list DHEA as an anabolic steroid under the Controlled Substances Act (1"The Tan Sheet" March 19, 2007, In Brief and 2"The Tan Sheet" March 12, 2007, In Brief)...
You may also be interested in...
Oregon DHEA bill
School employees would be prohibited from knowingly endorsing or suggesting the ingestion of any performance-enhancing supplement to students under a bill recently introduced by Oregon Senate President Peter Courtney, D-Salem. The legislation, SB 517, also contains provisions that would partner the Department of Education with voluntary organizations to develop educational programs for students to prevent the use of steroids and performance-enhancing supplements. The Act is declared an "emergency" measure and would punish violators with three months imprisonment or $500 or both. The bill passed the Senate Education and General Government subcommittee on March 13, according to Courtney's staff. Sen. Courtney introduced a similar bill in 2005. It passed the Senate but was defeated in the House...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.